



Attorney Docket No.: 5739.200-US

PATENT

#9  
LB  
5/25/00

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Weibel et al.

Application No.: 09/450,609

Group Art Unit: 1614

Filed: November 30, 1999

Examiner: J. Kim

For: New Pharmaceutical Composition And The Process For Its Preparation

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 96/18386
2. WO 95/06461
3. WO 92/17161
4. EP 0 945 134



It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

This information disclosure statement is being filed **after** the period set forth in 37 C.F.R. 1.97(b), but **before** the mailing date of either a final action or a notice of allowance, whichever occurs first.

Accompanying this information disclosure statement is (*check off either one*)

☒ a statement as specified in 37 C.F.R. § 1.97(e)

or


☐ the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c) (currently \$240.00). Charge Deposit Account No. 14-1447 in the amount of \$240.00. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: May 17, 2000

Carol E. Rozek  
Carol E. Rozek, Reg. No. 36,993  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

MAY 25 2000  
TECH CENTER 1600/2900



Attorney Docket No.: 5739.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Weibel et al.

Application No.: 09/450,609

Group Art Unit: 1614

Filed: November 30, 1999

Examiner: J. Kim

For: New Pharmaceutical Composition And The Process For Its Preparation

**STATEMENT UNDER 37 CFR 1.97(e)**


Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that each item of information contained in the information disclosure statement submitted herein was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Respectfully submitted,

Date: May 17, 2000

  
\_\_\_\_\_  
Carol E. Rozek, Reg. No. 36,993  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123